The symposia submission has now been closed.
Overview and topics
We welcome proposals for symposia of 75 min duration that integrate the latest advances in basic,
clinical, and translational neuropsychopharmacology, as well as biological psychiatry, drug
development, public policy issues relevant to mental health, mental illness, and treatment across
the lifespan. A comprehensive list of topics can be found here.
The International Scientific Program Committee also welcomes proposed symposia that link the latest ground-breaking preclinical developments with clinical research on a given topic. Through the free and open exchange of ideas, CINP supports a strong focus on new approaches to the development and assessment of CNS pharmaceuticals by researchers working in both academia and industry.
Symposia should be of 75 minutes duration, and should include three speakers, one of whom can, if desired, be the Chairperson of the session. Between them, the Chairperson and speakers should represent at least three different countries and institutions and we strongly encourage symposia proposals that include female faculty and early career investigators who have obtained their most recent degree within the last 10 years. At least one participant in all proposed symposia should be a CINP member.
All proposals should be submitted by the proposed Chairperson of the session. Submitters can propose a maximum of two symposia and speakers can agree to participate in a maximum of two proposals.
Timeline and Selection Process
|Symposia Submission Portal opens||May 2023|
|Symposia Submission Deadline||July 31st 2023
Extended until 8th August 2023
|Notification of Symposia Acceptance||By 29th September 2023|
CINP 2024 Symposia will be reviewed and selected on a highly competitive basis by the International Scientific Programme Committee during July and August 2023. Notifications will be sent to all symposia submitters in September 2023.
The congress registration fee will be waived for all confirmed speakers.
A sum 400,000 JPY approximately equivalent to 3,000 USD will be transferred to the Chairperson of the session once all speakers have confirmed their registration for the congress. This sum is intended to cover accommodation, flights and subsistence and should be distributed between the speakers at the discretion of the Chairperson.
Symposia Submission Guidelines
- Symposia submissions will be accepted in English only
- All submissions must be a maximum of 500 words
- A table or figure will count as 150 words
- The title, authors’ details, and references are not included in the total wordcount. CINP recommends using the NbN nomenclature for psychotropics (http://nbn2r.com)
- There is no fee for submitting a symposium proposal
- There is a maximum of 2 symposia submissions per person
Abstract submissions must be structured with the following:
- Description – 500-word abstract which describes the symposium and the role of each speaker
- Objectives – 100-word learning objectives for the symposia
- References – use Harvard style, where each reference is numbered in order of use
License of copyright and consent to publication
By submitting your symposium proposal, you confirm your agreement to the following conditions:
- All authors of the abstract have reviewed the proposal and confirm that all information is correct. It will be possible to edit your submission information until the submission deadline. The authors accept that the content of this proposal cannot be modified or corrected after the submission deadline, and they are aware that it will be published exactly as submitted
- Submission of the proposal constitutes consent of all authors of the proposal to publication (e.g. conference website, programs, other promotions, journal, etc.)
- All authors of the proposal warrant and represent that they either are the sole owners of, or have all necessary rights to sublicense, all the information and content in the proposal provided to CINP and its conference organizers and that publication of the proposal does not infringe any rights, including, but not limited to, intellectual property rights, of any third parties
- All authors of the proposal grant CINP a royalty-free, perpetual, irrevocable, and nonexclusive license to use, reproduce, publish, translate, distribute, and display the abstract
- All authors of the proposal grant exclusive permission to CINP to record the audio and video portion, if any, of the abstract presentation at the conference and to collect and retain all revenues from all rebroadcasts (including web broadcasts), sales, and publications of such recordings
- CINP reserves the right to remove from any publication any proposal that does not comply with the above
- The contact details saved in the CINP proposal submission system are those of the authors or faculty listed in the proposal, who will be notified about the status of the proposal. The submitter of the proposal is responsible for informing the other authors about the status of the proposal. If the proposal is accepted for presentation, it is also the submitting author’s responsibility to confirm or decline the proposal’s presentation at the meeting.
- The Chairperson of each symposium is responsible for ensuring the in-person participation of three speakers in the session. If any speaker is unable to attend, the Chairperson confirms that he/she will find a substitute who will participate in-person.
- If their abstract is a proposal for presentation at the Congress, it may be published on the Congress website or elsewhere, either prior to or contemporaneously with the Congress and/or in an abstract book that may be distributed electronically.
All submitted proposals will be reviewed by the International Scientific Programme Committee and submitters will be informed whether successful or otherwise in September 2023. Each proposal will be judged on objective evidence on the following criteria:
- Relevance to CINP
- Scientific and clinical impact
- Diversity of speakers
The CINP International Scientific Programme Committee welcomes the proposal of symposia
that link the latest, and ground-breaking, preclinical developments with the clinical research on a
given topic. Through the free and open exchange of ideas, CINP supports a strong focus on new
approaches to the development and assessment of CNS pharmaceuticals by researchers working in both
academia and industry.
Please find below the list of topics:
|Topic 1: Research||Topic 2: By Disorder||Topic 3: By Drug Methodology|
|• Clinical||• Addiction Disorders||• Animal Models||• Preclinical||• Anxiety Disorders||• Anxiolytics|
|• Translational||• Attention Deficit Disorders||• Brain Stimulation|
|• Others||• Autism||• Computational Neuroscience||• Bipolar Disorders||• Drugs for Bipolar Disorders|
|• Childhood & Adolescent Disorders||• Drugs for Depression|
|• COVID-19||• Drugs for Insomnia|
|• Dementia||• Drugs for Psychosis|
|• Depression||• Ethics of Psychopharmacology|
|• Eating Disorders||• Genetics|
|• Epilepsy||• History of Psychopharmacology|
|• Obsessive-Compulsive Disorders||• Imaging|
|• Pain||• Molecular Neurobiology/Pharmacology|
|• Panic Disorders||• Neuropathology/Post-Mortem Studies|
|• Personality Disorders||• Neurophysiology|
|• Post-Traumatic Stress Disorders||• Oriental Medicine|
|• Premenstrual Dysphoric Disorder||• Pharmacoeconomics|
|• Schizophrenia||• Pharmacogenetics/Kinetics|
|• Sexual Disorders||• Psychoneuroimmunology|
|• Sleep Disorders||• Transcultural Psychopharmacology|
|• Suicide||• Others|